# GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

> **NCT05054751** · PHASE3 · COMPLETED · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 275 (actual)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** GB491+ Fulvestrant
- **DRUG:** Placebo+Fulvestrant

## Key facts

- **NCT ID:** NCT05054751
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2022-12-02
- **Final completion:** 2024-03-30
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054751, "GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05054751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*